Ray Takigiku (Past Speaker)

Co-founder of Propel Labs, PharmaLegacy and Bexion Pharmaceuticals.  Previously, Ray was at Procter & Gamble Pharmaceuticals, and was also interim co-Director of the Genome Research Institute (now the Reading Campus) of the College of Medicine, University of Cincinnati. His early research interests were in the origin, evolution and sustainability of life.  Ray has over 30 years of experience in the discovery, development, and market support of pharmaceuticals, and was on the leadership team behind the blockbuster osteoporosis drug Actonel. Bexion now has a novel compound in clinical development for solid tumors, including glioblastoma multiforme, a deadly form of brain cancer; and potential for other rare tumors.  Ray is currently a board member of several corporate and non-profit organizations, including HealthSource of Ohio.  Ray received his undergraduate degrees from University of Colorado in Chemistry and Molecular Biology, his PhD in Chemistry from Indiana University, and business training from the Kellogg School of Management.